The Roches

Come winter and there is a surge of flu cases. Read More

ZURICH—Roche Holding AG Thursday kicked off what is likely to turn out to be a tepid pharmaceuticals reporting season, registering a double-digit drop in quarterly sales owing to a strong Swiss franc and fewer sales of its cancer drug Avastin. Read More

A new skin-cancer treatment that promises to shrink tumors and prolong the lives of patients with a particular genetic mutation won speedy approval that signals U.S. regulators' enthusiasm for such targeted therapies. Read More

Read More

In what looked like much better news for Roche in the breast cancer arena, Roche and ImmunoGen reported in October initial findings from a randomized Phase II trial testing T-DM1 as a first-line treatment of Her2+ metastatic breast cancer in 137 patients with no prior chemotherapy. Read More

Swiss drugmaker Roche is to implement a major cost-cutting and business review "in view of mounting pressures to curb healthcare costs," according to a company press statement . Read More

Under "mounting pressure to control health care costs," Roche will undertake an "operational excellence initiative" that could lead to cuts across the global drug maker's sites, including Genentech Inc. , in 2011 and 2012. Read More

A Swiss newspaper reported over the weekend that Roche is planning large cuts, across much of their multinational organization. Read More

Roche Holding has received a series of body blows this year. Read More